A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
Negredo Puigmal, Eugènia (Universitat Autònoma de Barcelona. Departament de Medicina)
Jiménez, Montse (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Loste, Cora (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Urrea, Victor (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Echeverría, Patricia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Bonjoch, Anna (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina)
Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)

Date:	2020
Abstract:	Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Forty-two PLWH aged ≥40 years receiving a protease inhibitor (PI)-based regimen were randomized (1:1) to switch from PI to Raltegravir (n = 20), or to remain on PI (n = 22). After 24 weeks, all patients received atorvastatin 20mg/day for 48 weeks. We analyzed plasma inflammatory as well as T-cell maturation, activation, exhaustion and senescence markers at baseline, 24 and 72 weeks, Plasma inflammatory markers remained unchanged. Furthermore, no major changes on T-cell maturation subsets, immunoactivation, exhaustion or immunosenescence markers in both CD4 and CD8 T cell compartments were observed. Only a modest decrease in the frequency of CD38 + CD8 T cells and an increase in the frequency of CD28 - CD57 + in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group. The study combined antiretroviral switch to Raltegravir and Statin-based anti-inflammatory strategies to reduce inflammation and chronic immune activation in PLWH. Although this combination was safe and well tolerated, it had minimal impact on inflammatory and immunological markers.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	PloS one, Vol. 15 (september 2020) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0238575
PMID: 32941476

15 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles